TABLE 4.

Concentrations of OPT-80 and the primary metabolite, OP-1118, versus day of sample collection in the single-dose study^a

Subject	Dose (mg)	Concn (μg/g feces) of indicated drug or metabolite on day:
		1		2		3		4		5
		OPT-80	OP-1118	OPT-80	OP-1118	OPT-80	OP-1118	OPT-80	OP-1118	OPT-80	OP-1118
009	200	17.1	31.6	225.5	832.8	164.5	623.9	79.9	333.6	NCb	NC
010	200	<LLOQ	<LLOQ	15.1	57.9	493.7	608.2	161.1	254.8	64.4	NC
011	200	<LLOQ	<LLOQ	252.8	632.1	59.6	136.2	11.5	24.7	<LLOQ	<LLOQ
013	200	139.5	297.4	247.3	466.3	91.9	212.6	12.2	26.0	5.4	13.7
014	200	<LLOQ	<LLOQ	299.8	616.0	115.2	258.1	38.5	97.1	4.2	14.0
016	200	47.6	137.6	221.7	757.4	193.1	750.6	22.3	81.2	5.0	17.1
001	300	269.4	399.5	21.2	46.7	2.1	4.6	<LLOQ	<LLOQ	NC	NC
002	300	<LLOQ	<LLOQ	3.0	<LLOQ	173.1	254.4	101.0	226.5	12.1	36.4
003	300	<LLOQ	<LLOQ	9.8	17.4	107.7	351.8	251.0	805.7	NC	NC
005	300	129.7	67.8	158.4	236.1	4.4	<LLOQ	NC	NC	NC	NC
006	300	17.5	38.7	492.1	680.5	83.2	128.4	2.6	<LLOQ	NC	NC
008	300	58.5	101.5	480.7	908.8	214.1	427.8	11.0	24.1	3.0	<LLOQ

^aData are not presented for the 100- and 450-mg dose groups, who completed the study as outpatients.

^bNC, not collected.